Empagliflozin benefits in patients with heart failure and preserved ejection fraction

被引：0
|
作者：
机构：
来源：
Nature Medicine | 2022年 / 28卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Subgroup analysis of the EMPEROR-Preserved clinical trial of the glucose-lowering drug empagliflozin in chronic heart failure with left ventricular ejection fraction (LVEF) >40% found improved clinical outcomes in the cohort of patients with LVEF ≥50%. This is, to our knowledge, the first time a drug therapy has been unequivocally demonstrated to benefit this patient population.
引用
收藏
页码：2480 / 2481
页数：1
相关论文
共 50 条
  • [31] Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial
    Butler, Javed
    Filippatos, Gerasimos
    Siddiqi, Tariq Jamal
    Brueckmann, Martina
    Bohm, Michael
    Chopra, Vijay K.
    Ferreira, Joao Pedro
    Januzzi, James L.
    Kaul, Sanjay
    Pina, Ileana L.
    Ponikowski, Piotr
    Shah, Sanjiv J.
    Senni, Michele
    Vedin, Ola
    Verma, Subodh
    Peil, Barbara
    Pocock, Stuart J.
    Zannad, Faiez
    Packer, Milton
    Anker, Stefan D.
    CIRCULATION, 2022, 145 (03) : 184 - 193
  • [32] Design and rationale of the EMPEROR trials of empagliflozin in patients with chronic heart failure with reduced or preserved ejection fraction
    Anker, S. D.
    Zannad, F.
    Butler, J.
    Filippatos, G.
    Salsali, A.
    Kimura, K.
    Schnee, J.
    Zeller, C.
    Pocock, S.
    George, J. T.
    Brueckmann, M.
    Packer, M.
    DIABETOLOGIA, 2018, 61 : S324 - S324
  • [33] Spironolactone in patients with heart failure and preserved ejection fraction
    Sanchez-Sanchez, C.
    Mendoza-Ruiz de Zuazu, H. F.
    Formiga, F.
    Manzano, L.
    Ceresuela, L. M.
    Carrera-Izquierdo, M.
    Gonzalez Franco, A.
    Epelde-Gonzalo, F.
    Cerqueiro-Gonzalez, J. M.
    Montero-Perez-Barquero, M.
    REVISTA CLINICA ESPANOLA, 2015, 215 (06): : 301 - 307
  • [34] Hospitalisation in Patients With Heart Failure With Preserved Ejection Fraction
    Nanayakkara, Shane
    Patel, Hitesh C.
    Kaye, David M.
    CLINICAL MEDICINE INSIGHTS-CARDIOLOGY, 2018, 12
  • [35] Treatment of patients with heart failure and preserved ejection fraction
    Deswal A.
    Bozkurt B.
    Current Treatment Options in Cardiovascular Medicine, 2008, 10 (6) : 516 - 528
  • [36] Outcomes in Patients with Heart Failure with Preserved Ejection Fraction
    Poppe, Katrina K.
    Doughty, Robert N.
    HEART FAILURE CLINICS, 2014, 10 (03) : 503 - +
  • [37] Irbesartan in patients with heart failure and preserved ejection fraction
    Forman D.
    Gaziano J.M.
    Current Cardiovascular Risk Reports, 2009, 3 (5) : 311 - 312
  • [38] Spironolactone in patients with heart failure and preserved ejection fraction
    Nunez, J.
    Nunez, E.
    Sanchis, J.
    REVISTA CLINICA ESPANOLA, 2016, 216 (02): : 111 - 111
  • [39] Empagliflozin Improves the MicroRNA Signature of Endothelial Dysfunction in Patients with Heart Failure with Preserved Ejection Fraction and Diabetes
    Mone, Pasquale
    Lombardi, Angela
    Kansakar, Urna
    Varzideh, Fahimeh
    Jankauskas, Stanislovas S.
    Pansini, Antonella
    Marzocco, Stefania
    De Gennaro, Stefano
    Famiglietti, Michele
    Macina, Gaetano
    Frullone, Salvatore
    Santulli, Gaetano
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2023, 384 (01): : 116 - 122
  • [40] COST-EFFECTIVENESS OF DAPAGLIFLOZIN VS. EMPAGLIFLOZIN IN PATIENTS WITH HEART FAILURE AND PRESERVED EJECTION FRACTION
    Rane, A.
    Nechi, R. N.
    Imam, M.
    Zoni, C. R.
    Ndikumukiza, C.
    Karaye, I
    Yunusa, I
    Alanazi, A.
    VALUE IN HEALTH, 2023, 26 (06) : S99 - S99
12345